Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2023-03-22 Regulatory Filings
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC. Form S-8 is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. The document includes details about the registration of additional shares under the company's 2019 Equity Incentive Plan and 2019 Employee Stock Purchase Plan. It references incorporation by reference of prior filings such as the Annual Report on Form 10-K and other SEC filings, but the document itself is a registration statement for securities issuance, not a financial report or earnings release. It is not an announcement of a report but a regulatory filing related to securities registration. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (9088 characters) and content confirm it is a full filing, not a brief announcement or certification only.
2023-03-22 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-17 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-17 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-17 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-17 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.